University of Sussex
Browse
Effectiveness and predictors of discontinuation of aripiprazole long acting injection.pdf (300 kB)

Effectiveness and predictors of discontinuation of aripiprazole long-acting injection: a 12-month naturalistic cohort study

Download (300 kB)
journal contribution
posted on 2023-06-09, 23:29 authored by Romaisa Aftab, Marco Pereira, Jed Hewitt, Ray Lyon, Richard Whale
Purpose/Background This study aimed to explore the discontinuation rate of aripiprazole long-acting injection (LAI) in a naturalistic clinical setting. Methods/Procedures A retrospective cohort study of 1 year duration was conducted on the first 200 patients registered to receive aripiprazole LAI in Sussex, UK. Rate of discontinuation and the association of robustly recorded clinical variables with discontinuation or a new acute care episode were explored. Findings/Results Of 200 registered, 173 patients initiated aripiprazole LAI and 40% discontinued this by 1 year. Mean discontinuation time was 18 weeks. The commonest discontinuation reason was “patient choice,” independent of efficacy or adverse effects. Not having a diagnosis of schizophrenia spectrum was the only variable significantly associated with treatment continuation after 1 year. No single diagnostic group accounted for this, although a greater continuation rate was observed in those with bipolar disorder. Illness severity factors at baseline, including apparent treatment resistance, had no impact on later aripiprazole LAI discontinuation or on acute service use over the year. Medication-related variables had no identified impact on acute service use. Implications/Conclusions This study supports the clinical utility of aripiprazole LAI for its licensed indications. The 1-year discontinuation rate is equivalent to that in reports of similarly designed studies of paliperidone LAI. Further exploration of nonmedication factors influencing LAI discontinuation is required. Preferential use of aripiprazole LAI over other medications may be supported due to fewer associated metabolic adverse effects.

History

Publication status

  • Published

File Version

  • Accepted version

Journal

Journal of Clinical Psychopharmacology

ISSN

0271-0749

Publisher

Lippincott, Williams & Wilkins

Issue

4

Volume

41

Page range

478-483

Department affiliated with

  • BSMS Publications

Full text available

  • Yes

Peer reviewed?

  • Yes

Legacy Posted Date

2021-04-08

First Open Access (FOA) Date

2022-07-02

First Compliant Deposit (FCD) Date

2021-04-08

Usage metrics

    University of Sussex (Publications)

    Categories

    No categories selected

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC